475 related articles for article (PubMed ID: 19142106)
1. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
2. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
[TBL] [Abstract][Full Text] [Related]
4. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
Preskorn SH
J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.
Wright CW; Aikman MS; Werts E; Seabolt J; Haeusler JM
Clin Ther; 2009 Nov; 31(11):2722-34. PubMed ID: 20110014
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
7. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
8. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
9. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.
Hynninen VV; Olkkola KT; Bertilsson L; Kurkinen K; Neuvonen PJ; Laine K
Clin Pharmacol Ther; 2008 Feb; 83(2):342-8. PubMed ID: 17687273
[TBL] [Abstract][Full Text] [Related]
10. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
[TBL] [Abstract][Full Text] [Related]
11. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.
Lobello KW; Preskorn SH; Guico-Pabia CJ; Jiang Q; Paul J; Nichols AI; Patroneva A; Ninan PT
J Clin Psychiatry; 2010 Nov; 71(11):1482-7. PubMed ID: 20441720
[TBL] [Abstract][Full Text] [Related]
13. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
[TBL] [Abstract][Full Text] [Related]
17. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
Patroneva A; Connolly SM; Fatato P; Pedersen R; Jiang Q; Paul J; Guico-Pabia C; Isler JA; Burczynski ME; Nichols AI
Drug Metab Dispos; 2008 Dec; 36(12):2484-91. PubMed ID: 18809731
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 2D6 genotype variation and venlafaxine dosage.
McAlpine DE; O'Kane DJ; Black JL; Mrazek DA
Mayo Clin Proc; 2007 Sep; 82(9):1065-8. PubMed ID: 17803873
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.
Levin GM; Nelson LA; DeVane CL; Preston SL; Eisele G; Carson SW
Psychopharmacol Bull; 2001; 35(2):62-71. PubMed ID: 12397887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]